MBX MBX Biosciences, Inc. Common Stock

QT90

Latest market price

56.63

+2.23+4.09%

Overview Short InterestFilings

MBXQT90MBX Biosciences, Inc. Common Stock·NASDAQ

Overview Short InterestFilings

56.63+4.09%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

BEAM+3.11%$26.68 ADMA+2.17%$11.30 NRIX+1.50%$26.09 ZLAB+1.59%$22.01 VRDN+2.53%$25.94 PHVS+2.52%$34.38 TLX+0.06%$9.05 IMNM+1.97%$19.98

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.40	Insider Own	—	Shs Outstand	48.16M	Perf Week	8.17%

Market Cap	2.62B	Forward P/E	—	EPS next Y	-3.98	Insider Trans	-0.12%	Shs Float	20.95M	Perf Month	-7.02%

Enterprise Value	2.20B	PEG	—	EPS next Q	-0.83			Short Float	21.12%	Perf Quarter	-23.06%

Income	-105.00M	P/S	—	EPS this Y	—			Short Ratio	8.60	Perf Half Y	84.78%

Sales	0.00	P/B	6.39	EPS next Y	—	ROA	-23.93%	Short Interest	4.42M	Perf YTD	72.48%

Book/sh	8.51	P/C	6.25	EPS next 5Y	—	ROE	-26.01%	52W High	72.64 -22.04%	Perf Year	149.66%

Cash/sh	8.70	P/FCF	—	EPS past 3/5Y	—	ROIC	-28.56%	52W Low	20.21 180.20%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	7.00% 6.15%	Perf 5Y	—

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	3.41	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	18.08	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	50.19	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	18.08	EPS Q/Q	-34.48%	SMA20	3.70%	Beta	1.10	Target Price	100.00

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	—	SMA50	-5.53%	Rel Volume	0.64	Prev Close	54.40

Employees	63	LT Debt/Eq	0.01	Earnings	Nov 05	SMA200	19.18%	Avg Volume	508.48K	Price	56.63

IPO Date	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.32% —	Net Debt/EBITDA	—	Volume	326,392	Change	4.09%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-12-26	Reiterated	Stifel Nicolaus		$56 → $84
Oct-02-26	Reiterated	Guggenheim	Buy	$88 → $150
Aug-10-26	Reiterated	Truist Securities	Buy	$70 → $88
Aug-07-26	Reiterated	Barclays	Overweight	$70 → $88
Jul-23-26	Reiterated	UBS		$60 → $90
May-12-26	Reiterated	Stifel Nicolaus		$50 → $56
May-12-26	Reiterated	Barclays	Overweight	$66 → $70
May-11-26	Reiterated	Truist Securities	Buy	$50 → $70
Mar-09-26	Reiterated	Truist Financial		$50
Jan-27-26	Initiated	Barclays	Overweight	$66

Latest News· Times ET

Oct-19-26

Oct-19-2607:00AM

Microbix Attending & Presenting at IPVS 2026accessnewswire.com

Oct-13-26

Oct-13-2608:00AM

MBX Biosciences to Participate in Upcoming November Investor Conferencesglobenewswire.com

Oct-12-26

Oct-12-2603:19AM

Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84Benzinga

Oct-02-26

Oct-02-2605:05AM

Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150Benzinga

Sep-30-26

Sep-30-2606:21AM

MBX Biosciences (NASDAQ:MBX) Shares Climb 4.1% – Time to Buy?defenseworld.net

Sep-28-26

Sep-28-2610:25AM

Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On MondayBenzinga

Sep-25-26

Sep-25-2603:23AM

MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DEdefenseworld.net

Sep-23-26

Sep-23-2603:51PM

MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)seekingalpha.com

Sep-16-26

Sep-16-2603:21PM

MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

Sep-10-26

Sep-10-2604:08PM

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPHfool.com

07:44AM

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?fool.com

Sep-09-26

Sep-09-2608:00AM

MBX Biosciences to Participate in Upcoming Investor Conferencesglobenewswire.com

Sep-08-26

Sep-08-2608:00AM

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officerglobenewswire.com

04:51AM

Jupiter Topco LLC Acquires Shares of 10,300 MBX Biosciences, Inc. $MBXdefenseworld.net

Aug-28-26

Aug-28-2602:00PM

Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long TermSeekingAlpha

Company

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022
Total Revenue	0	0	0	0	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—
Gross Profit	0	0	0	0	—
Selling, General and Administrative Excl. Other	30	19	11	7	—
Research and Development	88	79	57	29	—
Other Operating Expense	0	0	0	-1	—
Operating Income	-118	-98	-68	-35	—
Interest Expense	0	0	0	0	—
Unusual Expense	—	—	—	—	—
Non-Operating Income (Expense)	14	11	6	3	—
Net Income Before Taxes	-105	-87	-62	-33	—
Income Taxes	0	0	0	0	—
Consolidated Net Income	-105	-87	-62	-33	—
Net Income From Continuing Operations	-105	-87	-62	-33	—
Net Income	-105	-87	-62	-33	—
EPS (Recurring)	-2.40	-2.38	-1.85	-1.02	—
EPS (Basic, Before Extraordinaries)	-2.40	-2.38	-1.85	-1.02	—
EPS (Diluted)	-2.40	-2.38	-1.85	-1.02	—
EBITDA	-108	-87	-62	-32	—
Other After Tax Adjustments	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—
Gross Margin	—	—	—	—	—
Operating Margin	—	—	—	—	—
Net Margin	—	—	—	—	—
Shares Outstanding	48	37	33	32	—
Market Capitalization	2,718	1,167	608	—	—
Operating Lease Expense	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Azoulay Salomon	Chief Medical Officer	Aug 04 '26	Sale	65.77	370	24,335	14,399	Aug 05
Azoulay Salomon	Chief Medical Officer	May 08 '26	Option Exercise	11.65	140,006	1,630,696	194,540	May 11
Azoulay Salomon	Chief Medical Officer	May 08 '26	Sale	38.36	70,003	2,685,515	14,769	May 11
Hawryluk P. Kent	President & CEO	May 06 '26	Sale	29.54	607	17,931	727,667	May 08
Azoulay Salomon	Chief Medical Officer	May 06 '26	Sale	29.54	231	6,824	14,769	May 08
Hawryluk P. Kent	President & CEO	Mar 13 '26	Buy	28.41	18,500	525,663	486,777	Mar 16
Hawryluk P. Kent	President & CEO	Feb 26 '26	Option Exercise	16.00	28,768	460,288	728,274	Feb 27
Hawryluk P. Kent	President & CEO	Oct 24 '25	Option Exercise	3.25	182,859	594,292	664,256	Oct 28
Hawryluk P. Kent	President & CEO	Oct 20 '25	Buy	13.64	20,000	272,790	468,277	Oct 21
Hoerter Steven L.	Director	Oct 17 '25	Buy	13.25	20,000	264,984	20,000	Oct 20
Heron Patrick J	Director, 10% Owner	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10
GORDON CARL L	Director, 10% Owner	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19
ORBIMED ADVISORS LLC	Director, 10% Owner	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19
ORBIMED ADVISORS LLC	Director, 10% Owner	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.